Ticker	Volume	Price	Price Delta
DJIA	15,307.20	-80.41	-0.52%
S&P 500	1,655.35	-13.81	-0.83%
Nasdaq	3,463.30	-38.82	-1.11%

Ticker

Volume

Price

Price Delta

DJIA

15,307.20

-80.41

-0.52%

S&P 500

1,655.35

-13.81

-0.83%

Nasdaq

3,463.30

-38.82

-1.11%

Ticker	Volume	Price	Price Delta
STOXX 50	2,835.01	+13.36	0.47%
FTSE 100	6,840.27	+36.40	0.53%
DAX	8,530.89	+58.69	0.69%

Ticker

Volume

Price

Price Delta

STOXX 50

2,835.01

+13.36

0.47%

FTSE 100

6,840.27

+36.40

0.53%

DAX

8,530.89

+58.69

0.69%

Ticker	Volume	Price	Price Delta
Nikkei	15,627.30	+246.24	1.60%
Hang Seng	23,261.10	-105.29	-0.45%
S&P/ASX 200	5,165.37	-14.69	-0.28%

Ticker

Volume

Price

Price Delta

Nikkei

15,627.30

+246.24

1.60%

Hang Seng

23,261.10

-105.29

-0.45%

S&P/ASX 200

5,165.37

-14.69

-0.28%

Human Genome Sciences, Oshkosh, Pfizer: U.S. Equity Preview

By Nikolaj Gammeltoft - 2010-12-03T23:12:47Z

Shares of the following companies may have unusual moves in U.S. trading on Dec. 6. Stock symbols are in parentheses.

Human Genome Sciences Inc. (HGSI US): The Rockville, Maryland-based drugmaker’s Benlysta, the first new treatment for lupus in 52 years, needs more review by U.S. regulators before it may be approved for sale. The Food and Drug Administration extended the deadline for a decision to March 10. Human Genome is developing the drug together with GlaxoSmithKline Plc (GSK US).

Oshkosh Corp. (OSK US): The maker of all-terrain blast- proof trucks for the military was awarded a $413.2 million firm- fixed-price contract for 1,800 family of medium tactical vehicles for the Army National Guard, the U.S. Defense Department said on its website.

Pfizer Inc. (PFE US): The world’s biggest drugmaker plans to seek regulatory approval next year in Europe and the U.S. to sell bosutinib for patients with chronic myeloid leukemia.

To contact the reporter on this story: Nikolaj Gammeltoft in New York at ngammeltoft@bloomberg.net.

To contact the editor responsible for this story: Nick Baker at nbaker7@bloomberg.net

More News:

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.